We assessed the strength of ERBB ligand–receptor communications received by cancer cells in each tumor sample from across all cancer and non-cancer cell-type populations in the TME (tumor-wide signaling) using the extended-expression product method (Aran et al, 2019; Armingol et al, 2021; Griffiths et al, 2025). This evidence concerns the gene EGFR and neoplasm.